Valeant’s Quarterly Revenue Trend and Estimates
Valeant Pharmaceutical’s (VRX) revenues decreased ~5.4% to ~$2.0 billion during the first quarter—compared to revenues of ~$2.1 billion during the first quarter of 2017. Valeant met Wall Street analysts’ revenue estimates and reported revenues of ~$1.995 billion—compared to estimates of ~$1.944 billion during the first quarter. Valeant reported organic growth of 2% in total revenues during the first quarter.